Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity

NCT07000955 · Active, not recruiting

Last updated 2026-05-28

This clinical trial is testing the safety and how the body processes a 15mg dose of the drug IBI362 in adults with moderate to severe obesity.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Phase1, Phase2

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 98 people

Who can join Ages 18–55 · all sexes

Timeline Started 2025-06 · est. completion 2027-05

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT07000955 ↗

Description as written by the study sponsor.

This study is a multicenter, randomized, partially double-blind (double-blind in both the IBI362 group and the placebo group, with the tirbopeptide group open), placebo and active drug controlled design study

Treatments tested

Tirzepatide Drug

Tirzepatide administered subcutaneously (SC) once a week.
Placebo Drug

Placebo administered subcutaneously (SC) once a week.
IBI362 Drug

IBI362 administered subcutaneously (SC) once a week.

Main thing measured	The Incidence of adverse events and serious adverse events during the treatment period
Sponsor	Innovent Biologics (Suzhou) Co. Ltd.
Conditions studied	Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07000955 ↗